FDA Approvals of 2012

>
19 of 39
<

Stribild

Drug: Stribild, also known as Quad
Generic molecules: elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate
Company: Gilead Sciences
Approval date: Aug. 27

The scoop: EvaluatePharma says Stribild will be one of the most widely used anti-virals by 2018 and puts its worldwide sales at $2.7 billion by then, which puts Quad at 27 on its list of top 50 drugs by 2018. Upon approval, critics jumped on the price of the drug--$28,500. Healthcare advocates and AIDS activists were among them, but they were also accompanied by business and industry analysts.